BackgroundBreast MRI is the imaging modality of choice in patients with palpable breast lesions unequivocal on mammography and ultrasonography. This study aims to evaluate the role of dynamic contrast-enhanced MRI (DCE-MRI) and apparent diffusion coefficient mapping in the characterization and differentiation of various palpable breast lesions. This prospective observational study was conducted in a tertiary care hospital between July 2019 and June 2021. Sixty-six patients with palpable breast lesions were undergone MRI scans of the breasts. The various palpable breast lesions were categorized according to the 5th edition BI-RADS lexicon. The sensitivity of ADC mapping and DCE-MRI was determined for differentiation of various palpable breast lesions according to the BI-RADS category and gold standard histopathological findings.ResultsOf 66 patients with palpable breast lesions, 36 patients (54.5%) were benign and 30 patients (45.5%) were malignant lesions. Malignant palpable breast lesions had a mean ADC value of 0.939 ± 0.166[SD] × 10−3mm2/s, and benign lesions had 1.891 ± 0.524[SD] × 10−3mm2/s where unpaired Studentt-test showed statistically significant difference ofPvalue 0.0005. BI-RADS 2 lesions had a mean ADC value of 2.056 ± 0.471[SD] × 10−3mm2/s, BI-RADS 3 had 1.314 ± 0.151[SD] × 10−3mm2/s, BI-RADS 4 had 0.935 ± 0.119[SD] × 10−3mm2/s, and BI-RADS 5 had 0.930 ± 0.943[SD] × 10−3mm2/s. BI-RADS 2 category showed optimal cutoff mean ADC of 1.508 × 10−3mm2/s with a sensitivity of 85.7% and specificity of 94.7%, BI-RADS 3 lesions had 1.208 × 10−3mm2/s with a sensitivity of 75% and specificity of 55.2%, BI-RADS 4 lesions had 1.064 × 10−3mm2/s with a sensitivity 80% and specificity of 67.9%, and BI-RADS 5 lesions had 1.013 × 10−3mm2/s with a sensitivity of 80% and specificity of 82.6%.ConclusionsBreast MRI is superior to the other imaging modalities for the characterization and differentiation of various palpable breast lesions. The combined use of ADC mapping and DCE-MRI had more sensitivity than conventional MRI, ADC mapping or DCE-MRI alone.